Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx @ Union Square: Colleen Cutcliffe, CEO, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Onyx @ Union Square: Helmy Eltoukhy, CEO, Guardant Health
Blood tests for cancer are here, and Guardant Health is leading the charge.
Onyx Studio Sessions: Paula Brown Stafford, CEO, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Mayo Clinic-backed, Halle Berry-approved: Pendulum’s Dr. Colleen Cutcliffe is tackling type 2 diabetes before it even starts.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
From paper to pancreas: how Aspect Biosystems is leading a bioprinting revolution
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
Could a single pill crack the code of treating Alzheimer's disease?
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
Top Satellite Events at JPM Week
If you're planning to attend JPM Week, here are the top satellite events that should be on your radar.
How Saama’s ‘Clinical-LM’ is Supercharging Global Drug Trials
As drugmakers face mounting complexity and cost in clinical trials, Saama’s AI-driven platform promises swifter, more precise results.
A CRO for biotechs to grow
Allucent is a new CRO with a new CEO on a mission to support young biotechs.
Is a world without eyedrops possible?
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.